Heparin clinical trials
Heparin is named as an intervention in 17 current clinical trials in our China, Canada, USA, France, Ireland, UK, Germany, Netherlands, Poland, Switzerland, Austria, Israel, Turkey, Belgium, Denmark, Brazil, Mexico and Australia registers. 13 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Boston Scientific Corporation (1). The most-studied condition is Pulmonary Embolism. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Where Heparin is approved
All regulators →Of the three regulators tracked here, the first to approve Heparin was the US, on 9 Feb 1939.
- 3 EU orphan designations, most recently for treatment of cystic fibrosis (22 May 2006, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Heparin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Heparin works
All drug targets →- Antithrombin-III activator ActivatorTarget: SERPINC1 serpin family C member 1✓ In ChEMBL and the Guide to Pharmacology
- COVID-19Phase 3
- Acute coronary syndromePhase 3
- Acute kidney injuryPhase 3
- Angina pectorisPhase 3
- Angina unstablePhase 3
- Cardiovascular disorderPhase 3
- Coronary artery disorderPhase 3
- Heart disorderPhase 3
- Kidney failurePhase 3
- Myocardial infarctionPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201657, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 4214, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Heparin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 6 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Heparin
17 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Heparin in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Heparin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Multicenter and randomised study on atrial fibrillation prevention after cardiac surgery with a 3-way comparison between standard of care, posterior pericardiotomy and a treatment bundle (colchicine, amiodarone and posterior pericardiotomy) (PREV-AF)
2025-523209-14-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Authorised | Clinique Saint Augustin | France |
|
A Phase II, randomized, blinded, dose selection study to assess safety and preliminary efficacy of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) administered locally to the site of arterio-venous fistula (AVF) surgery to facilitate maturation of hemodialysis (HD) vascular access in patients with end stage kidney disease (ESKD) (MATURATION)
2026-526207-30-00 · Not possible to specify
|
Phase 2 | Authorised | Aplagon Oy | Sweden, Spain, Finland |
Heparin across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
6 single-substance products containing Heparin on the HPRA medicines list.
- Heparin Sodium 10 IU/ml flushing solution for maintenance of patency of intravenous devicesPinewood Laboratories Ltd · PA0281/230/001 · Marketed
- Heparin sodium 1,000 IU/ml Solution for injection or concentrate for solution for infusion, 10ml ampoulesPinewood Laboratories Ltd · PA0281/229/002 · Marketed
- Heparin sodium 1,000 IU/ml Solution for injection or concentrate for solution for infusion, 5ml ampoulesPinewood Laboratories Ltd · PA0281/229/001 · Marketed
- Heparin sodium 1,000 IU/ml Solution for injection or concentrate for solution for infusion, 5ml vialsPinewood Laboratories Ltd · PA0281/229/004 · Marketed
- Heparin sodium 25,000 IU/ml Solution for injection or concentrate for solution for infusion, 0.2ml ampoulesPinewood Laboratories Ltd · PA0281/229/003 · Marketed
Supply shortages
- Heparin Sodium InjectionUS (FDA) · Current · updated 3 Nov 2026
Conditions studied with Heparin
15 conditionsAll 15 conditions
| Condition (as registered) | Trials |
|---|---|
| Pulmonary Embolism | 3 |
| Sepsis | 3 |
| Extracorporeal Membrane Oxygenation Complication | 2 |
| Interstitial Cystitis | 1 |
| Bladder Pain Syndrome | 1 |
| Central Line Associated Blood Stream Infections (CLABSI) | 1 |
| Venous Thromboembolism | 1 |
| ECMO | 1 |
| Cerebral Venous Sinus Thrombosis | 1 |
| End-Stage Kidney Disease (ESKD) | 1 |
| Cardiopulmonary Bypass | 1 |
| Obesity | 1 |
| Cardiac Disease | 1 |
| Lipoprotein Lipase Deficiency | 1 |
| Community-acquired Pneumonia | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Boston Scientific Corporation | 1 |
| Vaneltix Pharma, Inc | 1 |
| CorMedix Therapeutics | 1 |
| Nanjing First Hospital, Nanjing Medical University | 1 |
| Beijing Chao Yang Hospital | 1 |
| Chen Ying | 1 |
| Shen Lei | 1 |
| Beijing Tiantan Hospital | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Regeneron Pharmaceuticals | 1 |
| Jesper Kjaergaard | 1 |
| Laval University | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| Damian Ratano | 1 |
| Université de Sherbrooke | 1 |
+ 2 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Heparin trials
How many clinical trials are testing Heparin?
17 current trials in our China, Canada, USA, France, Ireland, UK, Germany, Netherlands, Poland, Switzerland, Austria, Israel, Turkey, Belgium, Denmark, Brazil, Mexico and Australia registers name Heparin as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Heparin trials recruiting patients?
Yes. 13 of the 17 trials are recruiting: 2 with sites in China, 5 with sites in Canada, 2 with sites in USA, 1 with sites in France, 1 with sites in Turkey, 1 with sites in Belgium, 1 with sites in Denmark, 1 with sites in Brazil, 1 with sites in Mexico and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Heparin clinical trials?
Boston Scientific Corporation (1), Vaneltix Pharma, Inc (1), CorMedix Therapeutics (1) and Nanjing First Hospital, Nanjing Medical University (1), among 17 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Heparin clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Heparin licensed in Ireland?
Yes. The HPRA medicines list includes 6 single-substance products containing Heparin, for example Heparin Sodium 10 IU/ml flushing solution for maintenance of patency of intravenous devices (Pinewood Laboratories Ltd). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Heparin shortage?
The registers we track list 1 entry for Heparin: US FDA: current. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Heparin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Heparin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Heparin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.